B7-33
Tried B7-33? Be part of the collective knowledge. Share your experience - your insights help others on their journey.
What Is B7-33?
B7-33 is a synthetic, single-chain peptidomimetic agonist of the relaxin family peptide receptor 1 (RXFP1), derived from the B-chain of human gene-2 relaxin. It is designed to replicate the vasoprotective and anti-fibrotic effects of native relaxin while being more cost-effective to produce and possessing improved pharmacological properties.
B7-33 Research & Studies
01 B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice ▸
This study found that B7-33 reduces heart damage and scarring after a heart attack by activating specific protective pathways without the side effects of traditional relaxin treatments.
View Study (PubMed)02 B7-33 replicates the vasoprotective functions of human gene-2 relaxin ▸
Research demonstrates that B7-33 effectively mimics the vascular benefits of human relaxin, promoting blood vessel health and reducing systemic vascular resistance.
View Study (PubMed)B7-33 User Reviews & Experiences
*Based on large scale analysis of publicly available user experiences
User interest is high due to its anti-fibrotic potential and cardiovascular benefits, though it is primarily discussed in specialized peptide and biohacking circles rather than general supplement forums.
B7-33 Benefits, Dosage & Side Effects
- Anti-Fibrotic Action: Reduces the buildup of scar tissue in organs like the heart and kidneys.
- Vasodilation: Promotes the widening of blood vessels, which can improve circulation and lower blood pressure.
- Extracellular Matrix Remodeling: Helps regulate the structural framework of tissues, aiding in repair and preventing stiffness.
- Cardiac Health: Highly effective in animal models for preventing adverse remodeling after myocardial infarction.
- Vascular Protection: Successfully replicates the beneficial effects of serelaxin on endothelial function.
- Targeted Activation: Shows functional selectivity for RXFP1, minimizing off-target signaling pathways.
- Research Dosing: Animal studies often utilize weight-based dosing; human anecdotal ranges typically fall between 1-5mg daily.
- Frequency: Due to its peptide nature, it is typically administered via subcutaneous injection daily or every other day.
- Loading Phase: Some users suggest a short high-dose period to achieve steady state, though this is not clinically validated.
- Blood Pressure Drops: Potential for hypotension due to its potent vasodilatory properties.
- Injection Site Reaction: Possible redness, itching, or swelling at the site of administration.
- Hypoglycemia: Minimal reports suggest potential interactions with glucose metabolism in sensitive users.
- Legal Status: Currently sold as a 'research chemical' and not approved by the FDA for human consumption.
- Sourcing: Primarily available through specialized peptide supply companies and compounding pharmacies.
Related Compounds
Community Reviews
Share your experience with B7-33 and help others make informed decisions.
Write a Review
Sign in to leave a review